Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Exploration if Saizen marketed solution for injection induces an immunogenic reaction
To determine whether the marketed Saizen solution for injection, administered according to the approved label for 9 months (39 weeks) in adults with GHD, induces the development of binding antibodies ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck Cancer
To compare the overall survival (OS) in subjects with R/M HNSCC treated with pembrolizumab compared to standard treatment.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process
1. To describe the seroprotection rate (SPR) one month after the third dose of vaccine for a modified process hepatitis B vaccine in healthy adults (≥50 years of age).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A study in adults who have ongoing asthma, using a new product at different doses
This adaptive design, dose-ranging study of MK-1029 will assess the dose-related efficacy and safety of MK-1029 compared with placebo using measures of lung function (forced expiratory volume in 1 sec...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
IMI/REL (MK-7655A) vs. PIP/TAZ in Treatment of Subjects with HABP/VABP
To determine the incidence rate of all-cause mortality through Day 28 post-randomization associated with treatment with IMI/REL compared to treatment with PIP/TAZ in subjects diagnosed with HABP/VABP ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude MK-3475-522 : étude de phase 3 randomisée comparant l’efficacité du pembrolizumab à celle d’un placebo, associé à une chimiothérapie, comme traitement néoadjuvant, ainsi que l’efficacité du pembrolizumab seul par rapport à un placebo, comme traitement adjuvant, chez des patients ayant un cancer du sein triple négatif et localement avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Le cancer du sein est le cancer le plus fréquent chez la femme. Il représente plus du tiers de l'ensemble des nouveaux cas de cancer chez la femme. Un cancer du sein résulte d'un dérèglement de certai...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Phase 2 Study of Posaconazole in Chagas Disease Estudio Fase 2 de Posaconazol en la Enfermedad de Chagas
Primary objective is to evaluate efficacy of Posaconazole versus placebo in reducing parasitemia measured by qualitative PCR at end of 120 days of follow-up post treatment.. Evaluar la eficacia ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude MK-3475-170/KEYNOTE-170 : étude de phase 2 ; évaluant l’efficacité du pembrolizumab (MK-3475), chez des patients ayant un lymphome médiastinal primitif à grandes cellules b en rechute ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
MK-3475-170/KEYNOTE-170 : Etude de phase II portant sur le pembrolizumab (MK-3475) chez des patients ayant un lymphome médiastinal primitif à grandes cellules B en rechute ou réfractaire.
Country
France
organs
Lymphomes non hodgkinien
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
Taste Assessment of Maxalt Oral Disintegrating Tablets in Children
To evaluate the palatability of Maxalt-MLT® ODT in pediatric migraineurs, ages 6 - 11 years.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Serono International
Update Il y a 4 ans
A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis
The primary objective is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis receiving re-treatment with rituximab.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next